$MANH

Hollembaek Linda T. sold $300K of MANH

Hollembaek Linda T. sold 1,579 shares of MANHATTAN ASSOCIATES INC (MANH) at $189.88 ($0.30M total) on 2026-08-06.

Original reporting
SEC EDGAR · Hollembaek Linda T.
Published Aug 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANH
Neutral
high confidence
Mentioned
$MANH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANHNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 1,579 shares at $189.8801, totaling about $299,820.68, with holdings after sale of 12,268 shares.

02

Market read

Traders may note insider selling, but there is no accompanying operational, financial, or regulatory catalyst in the text.

03

What to watch

The article provides no context on total compensation, tax planning, or whether other insiders sold/bought around the same time.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-10, transaction dated 2026-08-06

Background

This is an SEC Form 4 insider transaction disclosure for Manhattan Associates (MANH).

Company-level read

Ticker impact

$MANHNeutralHigh confidence
Context

MANH is the issuer of a Form 4 showing director Hollembaek Linda T sold 1,579 shares at $189.8801 on 2026-08-06.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company-specific news, guidance, or event.

Market effects

None indicated; this is a single-company insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted as discretionary selling, but insider sales are often liquidity-driven and not reliably predictive.

Key entities

  • MANHATTAN ASSOCIATES INC

    Company whose director insider sale is disclosed on Form 4.

  • Hollembaek Linda T.

    Director who sold 1,579 shares on 2026-08-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANHMed

Manhattan Associates, Agilysys, Guidewire Software, Pegasystems, and Teradata Stocks Trade Up, What You Need To Know

Shares of Manhattan Associates, Agilysys, Guidewire Software, Pegasystems, and Teradata rose in afternoon trading after strong quarterly earnings and optimistic corporate commentary about AI-driven growth in enterprise software. Salesforce, CrowdStrike, and Okta reported significant AI-related revenue increases, easing investor concerns about AI disruption. Pegasystems' stock is down 36.2% year-to-date but saw a 6.2% increase on the day.

$MANHMedAI 8/10

Manhattan Associates stock hits 52-week high at $220.61

Manhattan Associates (MANH) stock hit a 52-week high at $220.61, up 59% in six months. The company reported strong Q2 2026 earnings, beating estimates with $1.39 EPS on $297.8M revenue. Analysts raised price targets to $225 (Stifel) and $240 (Truist), citing cloud business growth. The stock has a P/E ratio of 61.92 and is considered overvalued by InvestingPro.

$MANHHighAI 9/10

Why Manhattan Associates (MANH) Stock Is Up Today

Manhattan Associates (NASDAQ: MANH) shares rose 22.6% after the company reported Q2 2026 adjusted earnings of $1.39 per share on $297.8 million revenue, beating analyst estimates. The firm raised full-year revenue guidance to a $1.16 billion midpoint and lifted adjusted EPS guidance to $5.47 at the midpoint.

$MANHMedAI 8/10

Manhattan Associates Inc (MANH)

Manhattan Associates (MANH) reported second-quarter results that beat guidance. The company said revenue rose 9% year over year to $298 million, above guidance of $287 million. Non-GAAP operating margin was 34.9%, versus 34.7% guided.